Investor's Business Daily • 8 hours ago
Trump's bashing of drug prices included no mention of R&D. Biomeds have huge R&D budgets. Without strong profits, new drugs don't happen.
Insider Monkey • 2 days ago
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Zacks • 3 days ago
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
Insider Monkey • 9 days ago
The market has been volatile due to elections and the potential of another Federal Reserve rate increase. Small cap stocks have been on a tear, as the Russell 2000 ETF (IWM) has outperformed the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of June. SEC filings and hedge fund […]
Zacks • 10 days ago
Intellipharmaceutics International Inc. (IPCI) announced that it has filed a new drug application (NDA) with the FDA for Rexista.
CNBC Videos • 2 days ago
Incyte president & CEO Herve Hoppenot speaks to CNBC's Meg Tirrell about the growth of bone marrow drug Jakafi, drug pricing under Donald Trump and the company's drug pipeline.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||80.13 x 100|
|Ask||107.73 x 100|
|Day's Range||99.72 - 106.53|
|52 Week Range||55.00 - 118.49|
|PE Ratio (TTM)||137.04|
|Earnings Date||Feb 9, 2017 - Feb 13, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||109.14|